Caveolin-1 mediates cellular distribution of HER2 and affects trastuzumab binding and therapeutic efficacy-Reference-Cited by-同舟云学术

Caveolin-1 mediates cellular distribution of HER2 and affects trastuzumab binding and therapeutic efficacy

Published:2018-12 Issue:1 Volume:9 Page:
ISSN:2041-1723
Container-title:Nature Communications
language:en
Short-container-title:Nat Commun

Author:

Pereira Patrícia M. R.,Sharma Sai Kiran,Carter Lukas M.,Edwards Kimberly J.,Pourat Jacob,Ragupathi Ashwin,Janjigian Yelena Y.,Durack Jeremy C.,Lewis Jason S.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry

Link

http://www.nature.com/articles/s41467-018-07608-w.pdf

Reference63 articles.

1. Slamon, D. J. et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244, 707–712 (1989).

2. Yan, M. et al. HER2 expression status in diverse cancers: review of results from 37,992 patients. Cancer Metast. Rev. 34, 157–164 (2015).

3. Slamon, D. J. et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235, 177–182 (1987).

4. Baselga, J. & Swain, S. M. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat. Rev. Cancer 9, 463–475 (2009).

5. Pereira, P. M. R., Abma, L., Henry, K. E. & Lewis, J. Imaging of human epidermal growth factor receptors for patient selection and response monitoring: From PET imaging and beyond. Cancer Lett. 419, 139–151 (2018).

Cited by 87 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Additional statin treatment enhances the efficacy of HER2 blockade and improves prognosis in Rac1-high/HER2-positive breast cancer;Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease;2024-12

2. A Comprehensive Review of HER2 in Cancer Biology and Therapeutics;Genes;2024-07-11

3. High Caveolin-1 mRNA expression in triple-negative breast cancer is associated with an aggressive tumor microenvironment, chemoresistance, and poor clinical outcome;PLOS ONE;2024-07-03

4. PD-L1 has a heterogeneous and dynamic expression in gastric cancer with implications for immunoPET;Frontiers in Immunology;2024-06-10

5. Mechanisms of action and resistance to anti-HER2 antibody-drug conjugates in breast cancer;Cancer Drug Resistance;2024-06-03